FDA Approves Roche’s Enspryng for Thyroid Eye Disease

FDA approved Roche unit Genentech’s Enspryng for adults with thyroid eye disease. Enspryng becomes the first at-home subcutaneous treatment for the condition, with maintenance dosing every four weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via (Ref. ID: 202610160100BIZWIRE_USPR_____20261015_BW174934) on October 16, 2026, and is solely responsible for the information contained therein. (C)